NCT07200583Completed
Protein A Immunoadsorption in Highly Sensitized Haplo-HSCT Patients
Efficacy and Safety of Protein A Immunoadsorption-Based Desensitization in Highly Sensitized Haploidentical Hematopoietic Stem Cell Transplantation: A Single-Center Retrospective Study
Source: ClinicalTrials.gov · Last updated 18 Nov 2025
Brief summary (registry, in English)
This study reviews patients who received haploidentical hematopoietic stem cell transplantation (haplo-HSCT). Some patients develop donor-specific antibodies (DSA), which can block engraftment and cause transplant failure. Before transplant, a treatment called protein A immunoadsorption (a blood purification method to remove antibodies) was used, sometimes with additional medications. The study aims to see whether this approach lowers antibody levels, increases the chance of successful engraftment, reduces complications such as infections or graft failure, and improves short-term survival. The results may help guide safer and more effective transplants for highly sensitized patients.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 50 (actual)
- First submitted
- 23 Sept 2025
- Start date
- 31 May 2025
- Primary completion date
- 31 Aug 2025
- Lead sponsor
- Ting YANG
- Diseases
- Childhood cancers
- NCT number
- NCT07200583
What you commit to
- Study type: Observational
- Participants enrolled: 50
- From 31 May 2025 to the primary completion date, 31 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Missing critical data (e.g., incomplete DSA results, desensitization details, or follow-up outcomes).
- Inadequate follow-up (patients lost to follow-up or transferred to another hospital without accessible records).
- Patients who did not complete desensitization or did not undergo HSCT infusion.
Who the study is looking for
- Patients who received haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT) from a related donor (≥5/10 HLA match).
- Presence of donor-specific anti-HLA antibodies (DSA) before transplantation, with mean fluorescence intensity (MFI) above the positive threshold.
- Underwent desensitization therapy mainly based on protein A immunoadsorption (with or without additional agents such as rituximab or bortezomib), with complete treatment records.
- Successfully completed transplantation at the study center and had at least 100 days of follow-up.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350001 Coordinator of this site? Confirm its status | Fuzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.